# Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC

> **NCT03300115** · PHASE2 · UNKNOWN · sponsor: **Hangzhou ACEA Pharmaceutical Research Co., Ltd.** · enrollment: 222 (estimated)

## Conditions studied

- Metastatic Non-small Cell Lung Cancer

## Interventions

- **DRUG:** AC0010

## Key facts

- **NCT ID:** NCT03300115
- **Lead sponsor:** Hangzhou ACEA Pharmaceutical Research Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-18
- **Primary completion:** 2019-06-17
- **Final completion:** 2020-12-17
- **Target enrollment:** 222 (ESTIMATED)
- **Last updated:** 2019-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03300115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03300115, "Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03300115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*